Webpackaging logo

Nemera breaks ground in Brazil through Milfra acquisition

South America, Brazil, Health

With this acquisition Nemera establishes an operational footprint in Brazil and expands its product and services offering to better serve the pharmaceutical industry in Latin America

Nemera today announced that they have entered into an agreement to acquire Milfra. Milfra, based in Jaguariuna, state of São Paulo, Brazil, specializes in the development and production of both vaginal and rectal applicators, as well as oral dosers for the pharmaceutical industry. A family-owned company founded in 1966, Milfra is known for its expertise in high quality and high volume molding and assembly of devices and applicators.

This strategic acquisition expands Nemera’s global footprint in Latin America, extends its product offering and provides a foundation for future contract manufacturing services; thereby reinforcing its overall commitment to serving local markets. By integrating a key applicator pure player, Nemera will now be able to address specific patient and customer needs in the fields of gynecology and urology in Brazil.

Nemera has appointed Roberto Restivo as the General Manager of the new Nemera manufacturing facility in Brazil. As a seasoned international leader, Roberto brings in a wealth of experience in several industry sectors, including medical, plastics and aerospace. Roberto has held management positions with responsibility for a wide range of fields including sales & business development, finance, industrial operations and strategy & acquisitions. Roberto, supported by the previous family owners, will ensure a smooth transition with Milfra’s existing leadership team, and he will continue to develop and grow the local Nemera team and business in the future.

Marc Hämel, CEO of Nemera said, “This acquisition opens-up new opportunities for Nemera in Brazil and Latin America in general. It will enable us to better understand and serve even more patients with different needs. We feel privileged by the opportunity to integrate a new and unique culture to our already international company. Despite the tough sanitary situation and the restrictions to travel, we have already established a very good relationship with the Milfra leadership team and we have a very good feeling about their strong company culture and expertise.”

“Since we began our first discussions with the Nemera team, I was convinced that becoming part of the Nemera family was the perfect match for Milfra. We fully align with Nemera’s vision of becoming the most patient-centric drug device solutions company in the world. After a long history of manufacturing in Brazil it is fantastic to enable Nemera to operate in Brazil.” added Francisco Pofirio, owner of Milfra.

See also

Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

  • Company News
  • English
  • Modified 05 Aug 2021
  • Hits 401